{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:13:18Z","timestamp":1740107598621,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T00:00:00Z","timestamp":1549756800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T00:00:00Z","timestamp":1549756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["FARM6T9CET"],"award-info":[{"award-number":["FARM6T9CET"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diabete Ricerca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2019,5,9]]},"DOI":"10.1007\/s00592-018-01278-2","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T09:37:01Z","timestamp":1549791421000},"page":"505-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study"],"prefix":"10.1007","volume":"56","author":[{"given":"Giovanni","family":"Sartore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-4691","authenticated-orcid":false,"given":"Nino Cristiano","family":"Chilelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Seraglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Ragazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Roverso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cosma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annunziata","family":"Lapolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,10]]},"reference":[{"key":"1278_CR1","first-page":"737","volume":"8","author":"PW Wilson","year":"1988","unstructured":"Wilson PW, Abbott RD, Castelli WP (1988) High-density lipoprotein cholesterol and mortality. Framingham Heart Study Arterioscler 8:737\u2013741","journal-title":"Framingham Heart Study Arterioscler"},{"key":"1278_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.5551\/jat.E571","volume":"15","author":"D Sviridov","year":"2008","unstructured":"Sviridov D, Mukhaedova N, Remaley AT, Chin-Dusting J, Nestel P (2008) Antiatherogenic functionality of high-density lipoprotein: how much versus how good. J Atehroscler Thrombosis 15:52\u201362","journal-title":"J Atehroscler Thrombosis"},{"key":"1278_CR3","doi-asserted-by":"publisher","first-page":"15093","DOI":"10.1073\/pnas.0704602104","volume":"104","author":"N Terasaka","year":"2007","unstructured":"Terasaka N, Wang N, Yvan-Charvet L, Tall AR (2007) High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci 104:15093\u201315098","journal-title":"Proc Natl Acad Sci"},{"key":"1278_CR4","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.2174\/138161210791051031","volume":"16","author":"S Van Linkhout","year":"2010","unstructured":"Van Linkhout S, Spillmann F, Schultheiss H-P, Tschope C (2010) High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr Pharm Des 16:1504\u20131516","journal-title":"Curr Pharm Des"},{"issue":"1","key":"1278_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00592-013-0543-1","volume":"51","author":"G Daniele","year":"2014","unstructured":"Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J et al (2014) The inflammatory status score including IL-6, TNF-\u03b1, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51(1):123\u2013131","journal-title":"Acta Diabetol"},{"issue":"32","key":"1278_CR6","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.2174\/1381612811319320005","volume":"19","author":"TV Fiorentino","year":"2013","unstructured":"Fiorentino TV, Prioletta A, Zuo P, Folli F (2013) Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des 19(32):5695\u20135703","journal-title":"Curr Pharm Des"},{"key":"1278_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00125-006-0574-z","volume":"50","author":"E Nobecourt","year":"2007","unstructured":"Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F et al (2007) The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 50:643\u2013653","journal-title":"Diabetologia"},{"key":"1278_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.bbapap.2004.11.003","volume":"17","author":"U Panzenbock","year":"2005","unstructured":"Panzenbock U, Stocker R (2005) Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins. Biochim Biophys Acta 17:171\u2013181","journal-title":"Biochim Biophys Acta"},{"key":"1278_CR9","doi-asserted-by":"publisher","first-page":"847e55","DOI":"10.1194\/jlr.M800015-JLR200","volume":"49","author":"JW Brock","year":"2008","unstructured":"Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M et al (2008) Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res 49:847e55","journal-title":"J Lipid Res"},{"key":"1278_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.numecd.2014.12.004","volume":"25","author":"G Sartore","year":"2015","unstructured":"Sartore G, Seraglia R, Burlina S, Bolis A, Marin R, Manzato E et al (2015) High-density lipoprotein oxidation in type 2 diabetic patients and young patients with premature myocardial infarction. Nutr Metab Cardiovasc Dis 25:418\u2013425","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1278_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1466-5468.2005.01711c.x","volume":"22","author":"R Mukhtar","year":"2005","unstructured":"Mukhtar R, Reckless JPD (2005) Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. Diabetes Med 22:1\u201320","journal-title":"Diabetes Med"},{"key":"1278_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2337\/diacare.27.1.41","volume":"27","author":"JM Lawrence","year":"2004","unstructured":"Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP (2004) Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 27:41\u201346","journal-title":"Diabetes Care"},{"key":"1278_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.amjcard.2009.03.023","volume":"104","author":"R Spanheimer","year":"2009","unstructured":"Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonne B (2009) PROactive Investigators. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol 104:234\u2013239","journal-title":"Am J Cardiol"},{"key":"1278_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jdiacomp.2013.05.006","volume":"27","author":"H Mirmiranpour","year":"2013","unstructured":"Mirmiranpour H, Mousavizadeh M, Noshad S, Ghavami M, Ebadi M, Ghasemiesfe M et al (2013) Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: a randomized clinical trial. J Diabetes Complicat 27:501\u2013507","journal-title":"J Diabetes Complicat"},{"key":"1278_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.03.025","volume":"234","author":"H Koyama","year":"2014","unstructured":"Koyama H, Tanaka S, Monden M, Shoji T, Morioka T, Fukumoto S et al (2014) Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). Atherosclerosis 234:329\u2013334","journal-title":"Atherosclerosis"},{"key":"1278_CR16","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.numecd.2013.04.004","volume":"23","author":"NC Chilelli","year":"2013","unstructured":"Chilelli NC, Burlina S, Lapolla A (2013) AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a \u201cglycoxidation-centric\u201d point of view. Nutr Metab Cardiovasc Dis 23:913\u2013919","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1278_CR17","doi-asserted-by":"publisher","first-page":"670e6","DOI":"10.2337\/dc06-1508","volume":"30","author":"A Lapolla","year":"2007","unstructured":"Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R et al (2007) Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 30:670e6","journal-title":"Diabetes Care"},{"key":"1278_CR18","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.2337\/diabetes.54.7.2198","volume":"54","author":"M Passarelli","year":"2005","unstructured":"Passarelli M, Tang C, Mc Donald TO, O\u2019Brien KD, Gerrity RG, Heinecke JW et al (2005) Advanced glycation end product precursors impair ABCA-dependent cholesterol removal from cells. Diabetes 54:2198\u20132205","journal-title":"Diabetes"},{"key":"1278_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.numecd.2012.09.003","volume":"22","author":"O Vaccaro","year":"2012","unstructured":"Vaccaro O, Masulli M, Bonora E, Prato SD, Giorda CB, Maggioni AP et al (2012) Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial. Nutr Metab Cardiovasc Dis 22:997\u20131006","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1278_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/clinchem\/20.4.470","volume":"20","author":"CC Allain","year":"1974","unstructured":"Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20:470\u2013475","journal-title":"Clin Chem"},{"key":"1278_CR21","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1093\/clinchem\/28.10.2077","volume":"28","author":"P Fossati","year":"1982","unstructured":"Fossati P, Prencipi L (1982) Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 28:2077\u20132080","journal-title":"Clin Chem"},{"key":"1278_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11892-015-0633-2","volume":"15","author":"P Bjornstad","year":"2015","unstructured":"Bjornstad P, Cherney DZ, Maahs DM (2015) Update on estimation of kidney function in diabetic kidney disease. Curr Diabetes Rep 15:57","journal-title":"Curr Diabetes Rep"},{"key":"1278_CR23","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/clinchem\/40.6.882","volume":"40","author":"WY Craig","year":"1994","unstructured":"Craig WY, Poulin SE, Nelson CP, Ritchie RF (1994) An ELISA method for the detection of oxidized low-density lipoprotein: the effects of blocking buffer and the method of data expression on experimental findings. Clin Chem 40:882\u2013888","journal-title":"Clin Chem"},{"key":"1278_CR24","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1016\/S0021-9258(18)42741-X","volume":"267","author":"Z Makita","year":"1992","unstructured":"Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133\u20135138","journal-title":"J Biol Chem"},{"key":"1278_CR25","first-page":"155e70","volume":"128","author":"VN Schumaker","year":"1986","unstructured":"Schumaker VN, Puppione DL (1986) Sequential flotation ultracentrifugation. Methods Enzymol 128:155e70","journal-title":"Methods Enzymol"},{"key":"1278_CR26","first-page":"63","volume-title":"Manual of laboratory operations","author":"A Hainline","year":"1982","unstructured":"Hainline A, Karon J, Lippel K (1982) Lipid research clinics program: lipid and lipoprotein analysis. In: Hainline A, Karon J, Lippel K (eds) Manual of laboratory operations. US Dept Health and Human Services, Washington, DC, pp\u00a063\u201377"},{"key":"1278_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1258\/acb.2012.012019","volume":"50","author":"J McEneny","year":"2013","unstructured":"McEneny J, McPherson PA, McGinty A, Hull S, McCance DR, Young IS (2013) Pioglitazone protects HDL2&3 against oxidation in overweight and obese men. Ann Clin Biochem 50:20\u201324","journal-title":"Ann Clin Biochem"},{"key":"1278_CR28","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.2174\/13816128113199990298","volume":"19","author":"A Pirillo","year":"2013","unstructured":"Pirillo A, Norata GD, Catapano AL (2013) Treating high-density lipoprotein cholesterol (HDL-C): quantity versus quality. Curr Pharm Des 19:3841\u20133857","journal-title":"Curr Pharm Des"},{"key":"1278_CR29","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1182\/blood-2015-01-544676","volume":"125","author":"SX Gu","year":"2015","unstructured":"Gu SX, Stevens JW, Lentz SR (2015) Regulation of thrombosis and vascular function by protein methionine oxidation. Blood 125:3851\u20133859","journal-title":"Blood"},{"key":"1278_CR30","first-page":"1224","volume":"105","author":"B Shao","year":"2008","unstructured":"Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW (2008) Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. PNAS 105:1224\u20131229","journal-title":"PNAS"},{"key":"1278_CR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366 1279\u20131289","journal-title":"Lancet"},{"key":"1278_CR32","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M et al (2016) Pioglitazone after ischemic stroke or transient ischemic attack. NEJM 374:1321\u20131331","journal-title":"NEJM"},{"key":"1278_CR33","first-page":"578P","volume":"53","author":"S Mariz","year":"2004","unstructured":"Mariz S, Urquhart R, Moules I, Tan MH, Edwards G (2004) Effects of pioglitazone addition to metformin or sulfonylurea therapy on serum lipids in patients with type 2 diabetes mellitus: 2-year data. Diabetes 53:578P","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"1278_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00592-009-0150-3","volume":"47","author":"R Nerla","year":"2010","unstructured":"Nerla R, Pitocco D, Zaccardi F, Scalone G, Coviello I, Mollo R et al (2010) Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes. Acta Diabetol 47(Suppl 1):117 \u2013122","journal-title":"Acta Diabetol"},{"issue":"10","key":"1278_CR35","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00125-013-2976-z","volume":"56","author":"D Tripathy","year":"2013","unstructured":"Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S et al (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56(10):2153\u20132163","journal-title":"Diabetologia"},{"key":"1278_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127\u2013135","journal-title":"N Engl J Med"},{"key":"1278_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s001250050049","volume":"43","author":"CC Hedrick","year":"2000","unstructured":"Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM et al (2000) Glycation impairs high-density lipoprotein function. Diabetologia 43:312\u2013320","journal-title":"Diabetologia"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-018-01278-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-01278-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-01278-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T17:35:41Z","timestamp":1662917741000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-018-01278-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,9]]}},"alternative-id":["1278"],"URL":"https:\/\/doi.org\/10.1007\/s00592-018-01278-2","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"type":"print","value":"0940-5429"},{"type":"electronic","value":"1432-5233"}],"subject":[],"published":{"date-parts":[[2019,2,10]]},"assertion":[{"value":"13 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared they do not have anything to disclose regarding conflict of interest with respect to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}